Indaptus Therapeutics, Inc. (Nasdaq: INDP) announces financial results for Q3 2025, completing the Safety Lead-In cohort for Decoy20 and tislelizumab combination trial. $2.3 million raised in September 2025 through at-the-market facility to strengthen balance sheet. Efficacy evaluations ongoing, pausing enrollment for further assessment and development options.

Financials for Q3 2025: Research and development expenses increased to $1.52 million, up $50,000 from Q3 2024. General and administrative expenses decreased to $1.1 million, down $0.6 million from Q3 2024. Loss per share for Q3 2025 was $2.98, compared to $9.04 in Q3 2024. Cash and cash equivalents as of Sept. 30, 2025, were approximately $5.8 million.

Net cash used in operating activities for the nine months ended Sept. 30, 2025, was approximately $11.6 million, compared to $8.9 million in 2024. Net cash provided by financing activities for the nine months ended Sept. 30, 2025, was approximately $11.7 million, primarily from common stock issuance. Company expects current cash to support operations into Q1 2026.

Indaptus Therapeutics’ unique approach to cancer and viral infection treatments involves a multi-targeted immune system-activating signal package with the Decoy platform. Product candidates show promise in pre-clinical models for various cancers and viral infections. Forward-looking statements include expectations for ongoing activities and product candidate effects.

Unaudited Condensed Consolidated Balance Sheets show total assets of $6.84 million as of Sept. 30, 2025, with cash and cash equivalents of $5.83 million. Unaudited Condensed Consolidated Statements of Operations reveal a net loss of $2.98 million for Q3 2025. Cash flows from financing activities provided $11.67 million for the nine months ended Sept. 30, 2025.

Overall, Indaptus Therapeutics remains focused on innovative treatments for cancer and viral infections, with promising product candidates in development. Financial results show a strategic approach to funding and operational activities to support ongoing research and development efforts. Investors can expect further updates on the progress of combination trials and product candidate efficacy.

Read more at GlobeNewswire: Indaptus Therapeutics Reports Third Quarter 2025 Financial